Here are 1-3 brief analogies for Ernexa Therapeutics (ERNA):

• Like a clinical-stage BioNTech or Moderna, but focused on cancer and gene therapies.
• A startup CRISPR Therapeutics, but with additional programs in immuno-oncology and cell therapy.

• IRX-2: A clinical-stage immunotherapy drug candidate currently in a Phase 2b clinical trial for squamous cell cancer of the head and neck.
• Gene-editing and cell therapy programs: Therapeutic development platforms leveraging gene-editing and cell therapy technologies for treating oncology, blood disorders, and monogenic diseases.

Ernexa Therapeutics (ERNA) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer, blood disorders, and monogenic diseases. Its advanced programs are currently in clinical trials (Phase 2b).

As a clinical-stage company, Ernexa Therapeutics does not yet have commercially approved products available for sale. Therefore, the company does not have major customers in the traditional sense of selling its therapies to other companies or individuals.

Catalent, Inc. (CTLT)

Sanjeev Luther

President and Chief Executive Officer

Sanjeev Luther has served as President and Chief Executive Officer of Ernexa Therapeutics (formerly Eterna Therapeutics Inc.) since January 2024. With over 30 years of experience in the life sciences industry, he focuses on oncology, biotechnology innovation, and corporate leadership across global markets. Prior to joining Ernexa, Mr. Luther was President, CEO, and a Board Member of Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals) from November 2017 to December 2023. In this role, he oversaw the development of the company's pipeline for rare cancers and secured strategic partnerships, in-licensing, and out-licensing agreements. His career includes leadership positions at Fortune 500 corporations and startups, such as Mallinckrodt Pharmaceuticals, GE Healthcare, Bristol Myers Squibb, Bausch + Lomb, and Novartis, where he focused on commercial strategy, business development, and global expansion. He has experience guiding clinical-stage biopharmaceutical companies, managing global Phase 3 trials, securing capital through institutional investors and partnerships, and was a finalist for the EY Entrepreneur Of The Year® Award in New Jersey in 2019.

Sandra M. Gurrola

Senior Vice President, Finance, and Principal Financial and Accounting Officer

Sandra M. Gurrola serves as Senior Vice President of Finance and Principal Financial and Accounting Officer for Ernexa Therapeutics. She joined the company as Vice President of Finance in June 2021 and was promoted to Senior Vice President of Finance in May 2023. Her previous experience includes serving as Senior Vice President of eGames.com Holdings, LLC from March 2021 to June 2021. Before that, Ms. Gurrola held roles at NTN Buzztime, Inc., including Senior Vice President of Finance from September 2019 to March 2021, and Vice President of Finance from 2014 to 2019. From 2009 to 2014, she held various leadership accounting positions at NTN Buzztime, Inc., such as Controller, Director of Accounting, and Director of Financial Reporting and Compliance. Earlier in her career, she was a senior manager of financial reporting for Metabasis Therapeutics, Inc., a biotechnology company.

Dorothy Clarke

General Counsel

Dorothy Clarke is the General Counsel of Ernexa Therapeutics. She was appointed to the Board of Directors of Eterna Therapeutics (now Ernexa) in September 2023. Ms. Clarke has over 20 years of experience in various leadership positions at Johnson & Johnson across its pharmaceutical, medical devices & diagnostics, and consumer sectors. Her roles at Johnson & Johnson included Assistant General Counsel, Vice President of Regulatory Affairs, Chief Privacy Officer, Chief Compliance Officer for Medical Devices & Diagnostics, and Vice President of Research & Development, Innovation and Business Development Compliance. She was responsible for compliance, regulatory, and data protection functions, addressing regulatory inquiries and investigations, and conducting due diligence for numerous acquisitions. Prior to her tenure at Johnson & Johnson, she practiced law at Reinhart Boerner Van Deuren, S.C., and Fox, Bennett & Turner, where she represented pharmaceutical companies, patient advocacy groups, and healthcare organizations.

Robert Pierce, M.D.

Chief Scientific Officer

Dr. Robert Pierce serves as the Chief Scientific Officer for Ernexa Therapeutics. He is a physician-scientist with extensive expertise in cancer immunology and translational biomarker development. Dr. Pierce currently holds the position of Chief Medical Officer (consulting) at Attivare Therapeutics and previously served as their Chief Scientific Officer, focusing on an immunostimulatory scaffold platform. His experience includes leading major immuno-oncology research and development programs at Sensei Biotherapeutics, OncoSec Medical, Fred Hutchinson Cancer Research Center, and Merck. He contributed to the development of innovations such as the PD-L1 IHC companion diagnostic for pembrolizumab and has authored over 170 peer-reviewed publications. Dr. Pierce earned his M.D. from Brown University and his B.A. from Yale University.

Kanika Chawla, Ph.D.

Senior Vice President, Technical Operations (Consultant)

Dr. Kanika Chawla is the Senior Vice President, Technical Operations (Consultant) at Ernexa Therapeutics. She is a strategic and accomplished CMC leader with two decades of experience in CAR-T, cell therapy, and biologics. Her expertise spans process and analytical development, CMC strategy, and technical leadership from early-stage development through commercial launch. Most recently, Dr. Chawla led Process Sciences at Cargo Therapeutics, where she was instrumental in shaping CMC strategy and building manufacturing and analytical platforms for various CAR-T therapies. Before Cargo, she was the Head of Process Sciences at ArsenalBio, where she established the Technical Operations function and oversaw the development of a non-viral manufacturing platform. Earlier in her career, she directed analytical strategy at Vir Biotechnology and began her industry career at Cellerant Therapeutics. She holds a Ph.D. and M.S. in Bioengineering from the University of California, San Diego, and a B.S. in Chemical Engineering from the University of New Mexico.

The key risks for Ernexa Therapeutics (ERNA) are:

1. Funding and Going Concern Risk: Ernexa Therapeutics faces a severe risk to its business continuity due to insufficient financial resources. Management has explicitly warned that current resources are inadequate to fund operations for 12 months following the financial statement issuance date. The company has an accumulated deficit of approximately $245.6 million and relies heavily on future fundraising, making "going concern" a significant threat.
2. Clinical Trial and Regulatory Risk: As a preclinical-stage biopharmaceutical company focused on novel cell therapies, Ernexa Therapeutics' success hinges on the successful and timely completion of preclinical development, clinical trials, and ultimately, regulatory approvals for its product candidates, ERNA-101 and ERNA-201. The regulatory approval process for cellular immunotherapies and stem cell therapies is uncertain, potentially more expensive, and may take longer than for more established therapeutic approaches.
3. Technology and Competition Risk: Ernexa Therapeutics operates in a highly competitive and rapidly changing industry, developing innovative cell therapies using induced mesenchymal stem cells (iMSCs). The success of its pipeline candidates depends on the scientific validation of its iMSC platform. Competitors may develop more advanced, safer, or more effective therapies, which could adversely affect Ernexa's financial condition and market position.

Ernexa Therapeutics (symbol: ERNA) is a preclinical-stage biopharmaceutical company focused on developing cell therapies using gene-editing tools. The company's pipeline includes ERNA-101 for ovarian cancer and ERNA-102 for rheumatoid arthritis. The addressable markets for their main products and core technologies are outlined below:

Ovarian Cancer (ERNA-101)

As Ernexa Therapeutics' ERNA-101 targets ovarian cancer, a type of advanced solid tumor, its addressable market falls within the broader oncology cell and gene therapy markets.

• The global oncology cell therapy market is projected to reach approximately $25 billion by 2031. The United States is a dominant region in this market.
• Within the global cell therapy market, the oncology segment is anticipated to hold the largest market share, estimated at 70.2% in 2025.
• The global cancer gene therapy market size is expected to reach US$ 19.97 billion by 2033, with North America leading in revenue share.

Rheumatoid Arthritis (ERNA-102)

ERNA-102 is being developed for rheumatoid arthritis, an autoimmune disease. While specific market sizes for cell therapies in rheumatoid arthritis are not explicitly detailed in the available information, this product addresses the autoimmune disorders segment within the broader cell therapy market.

• Autoimmune disorders are a therapeutic area for cell therapies.

Overall Cell and Gene Therapy Market (Core Technologies)

Ernexa Therapeutics leverages cutting-edge gene-editing tools and cell therapy technology. Therefore, the overall markets for these technologies represent a significant addressable market.

• The global cell and gene therapy market size is expected to be worth around USD 119.30 billion by 2034, growing from USD 25.89 billion in 2025 with a CAGR of 18.5%. North America accounted for approximately 43% of the revenue share in 2024.
• Another estimate places the global cell and gene therapy market at USD 13.17 billion in 2025, projected to grow to USD 200.54 billion by 2034, exhibiting a CAGR of 35.60%. North America held a dominant market share of 40.10% in 2025.
• The global cell therapy market alone was estimated at USD 4.74 billion in 2023 and is projected to reach USD 20.07 billion by 2030, with a CAGR of 22.66% from 2024 to 2030. North America held the largest revenue share of 58.7% in 2023. It is also projected to reach USD 190.36 billion by 2034 with a CAGR of 40.78% from 2026.
• The global gene editing market size was estimated at USD 5.87 billion in 2025 and is projected to reach USD 18.55 billion by 2033, growing at a CAGR of 15.71% from 2026 to 2033. North America held the largest global share of 52.65% in 2025.
• The CRISPR-based gene editing market, a key component of gene editing, was valued at USD 7.25 billion in 2025 and is anticipated to reach approximately USD 28.77 billion by 2035, growing at a CAGR of 14.78% from 2026. North America dominated this market in 2025.

Share Repurchases

• Eterna Therapeutics (now Ernexa Therapeutics) authorized a stock repurchase program of up to $1 million of its outstanding common stock on November 25, 2024.

Share Issuance

• In February 2026, Ernexa Therapeutics completed a public offering that generated approximately $9.5 million in net proceeds.
• Ernexa Therapeutics secured approximately $7.1 million in total gross proceeds from a securities purchase agreement in 2025, with an initial closing of $1.1 million in April and a second closing of $6.0 million in June.
• In 2021, Brooklyn ImmunoTherapeutics, Inc. (a predecessor company) raised over $52 million in net proceeds through equity line sales of common stock.
• The company completed a $12.0 million gross Private Investment in Public Equity (PIPE) in March 2022 and secured a $5 million PIPE investment in 2024.

Inbound Investments

• A public offering in February 2026 brought in approximately $9.5 million in net proceeds.
• A private placement and securities purchase agreement in 2025 resulted in total gross proceeds of approximately $7.1 million.
• The company completed a $12.0 million gross Private Investment in Public Equity (PIPE) in March 2022 and secured a $5 million PIPE investment in 2024.

Outbound Investments

• In July 2021, Brooklyn ImmunoTherapeutics, Inc. acquired Eterna Therapeutics, Inc. for a total value of $125.0 million, paid with $17.4 million in cash and $107.6 million in common stock.

Capital Expenditures

• Ernexa Therapeutics reported capital expenditures of $369K in Q3 2024.